NMN: The NAD+ Precursor That Declines With Age | BioHackNZ Research

TL;DR
Nicotinamide mononucleotide (NMN) is a precursor to NAD+, a critical molecule for cellular energy production that declines with age. Human trials consistently show NMN raises blood NAD+ levels and is generally well tolerated. The strongest clinical signals to date include improved muscle insulin sensitivity in postmenopausal women with prediabetes, and modest benefits for walking speed and sleep quality in older adults. Evidence for broad performance enhancement remains limited and mixed. This review summarises the key peer-reviewed trials, practical dosing, and honest limitations.

Evidence Rating: ⭐⭐⭐⭐ Strong for raising NAD+ levels; ⭐⭐⭐ Promising for muscle insulin sensitivity (specific populations) and functional markers in older adults; ⭐⭐ Limited for general athletic performance.

What the Research Actually Shows

NAD+ Boosting

Multiple randomised controlled trials demonstrate that oral NMN reliably increases circulating NAD+ and related metabolites. This is the most consistent finding across the human literature and forms the foundation for interest in NMN as a cellular energy support nutrient.

Muscle Insulin Sensitivity

The landmark 2021 trial by Yoshino et al. (published in Science) showed that 250 mg/day NMN for 10 weeks improved muscle insulin sensitivity and insulin signalling in postmenopausal women with prediabetes who were overweight or obese. This remains one of the strongest outcome-focused human studies to date.

Physical Function in Older Adults

Trials in healthy older men and mixed older adult cohorts (Igarashi 2022; Morifuji 2024) reported that 250 mg/day NMN raised NAD+ levels, helped maintain walking speed, and improved aspects of sleep quality. Effects on grip strength and broader muscle function have been modest or mixed.

Performance & Energy

Some dose-dependent trials (notably Yi et al., 2023) found improvements in six-minute walk distance at higher doses (600–900 mg). However, systematic reviews of muscle mass and function outcomes in adults over 60 have not shown consistent, clinically meaningful benefits. Performance claims should therefore be treated with caution.

Key Benefits

  • Reliably increases blood NAD+ levels
  • May support muscle insulin sensitivity in postmenopausal women with metabolic risk
  • May help maintain walking speed and sleep quality in older adults
  • Generally well tolerated in studied doses (up to 900–1250 mg/day short-to-medium term)
  • Supports cellular energy pathways that decline with age

Key Studies

  • Yoshino M. et al. (2021) — RCT in postmenopausal prediabetic women. 250 mg/day NMN improved muscle insulin sensitivity. Science. DOI: 10.1126/science.abe9985
  • Igarashi M. et al. (2022) — RCT in healthy older men. 250 mg/day raised NAD+ and showed nominal improvements in gait speed and grip strength. npj Aging. DOI: 10.1038/s41514-022-00084-z
  • Yi L. et al. (2023) — Dose-dependent RCT (300/600/900 mg). Increased NAD+, improved 6-minute walk distance and self-reported health. GeroScience. DOI: 10.1007/s11357-022-00705-1
  • Pencina K.M. et al. (2023) — RCT in overweight/obese middle-aged and older adults. Raised NAD+, reduced body weight, diastolic blood pressure and LDL cholesterol. J Clin Endocrinol Metab. DOI: 10.1210/clinem/dgad027
  • Morifuji M. et al. (2024) — RCT in older adults. 250 mg/day for 12 weeks raised NAD+, maintained walking speed and improved sleep quality scores. GeroScience, 46(5), 4671–4688. DOI: 10.1007/s11357-024-01204-1

Expert Views

Dr. David Sinclair has been a prominent advocate for NAD+ precursors, including NMN, based on extensive preclinical work on ageing biology. Human translation remains an active area of research.

Dr. Peter Attia discusses NAD+ biology and precursors with measured interest, emphasising that while the mechanistic rationale is strong, robust long-term human outcome data are still limited.

Dr. Rhonda Patrick has covered NAD+ metabolism and its relevance to cellular energy and ageing in her research content.

NZ Context

Interest in NAD+ support and healthy-ageing nutrients is growing among New Zealanders, particularly those focused on maintaining energy, metabolic health and functional capacity with age. NMN remains a specialised import for most consumers. As with all supplements, quality and accurate labelling matter.

Practical Dosage Summary

  • Common studied doses: 250–900 mg per day
  • Many positive signals observed at 250–600 mg/day
  • Higher doses (600–900 mg) used in some performance and NAD+-maximising trials
  • Typically taken in the morning; consistency matters more than precise timing
  • No loading phase required

Safety Notes

NMN has shown a good short-to-medium-term safety profile in human trials up to approximately 1250 mg/day. Mild digestive discomfort is occasionally reported. Long-term safety data beyond several months remain limited. Discuss with your healthcare provider before use, especially if you have a medical condition or take prescription medications.

This is not medical advice. BioHackNZ provides general information based on published research. NMN is a complementary supplement and is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any supplement regimen. Individual results vary.

Last updated: 22 August 2026 | BioHackNZ Research Team

Shop Nicotinamide Mononucleotide (NMN)
View Product →

Back to blog